Uday Kompella's Laboratory

 

PROJECTS - FUNDING AGENCIES


Project (Role: Principal Investigator)

Funding Agency

Corneal and scleral permeability of drugs. Ophtha Technical Development, [01/05-12/05].

Novartis AG,
Basel
.
Anti-VEGF and antiproliferative effects of novel drugs.
[07/01/04-06/30/05]
.
Novacea, Inc.
Biocompatibility of SABER formulations in the eye. 
[07/01/04-06/30/05]
.
Durect Corporation.

Equipment for supercritical fluid processes. [06/01/04-05/31/05].

Nebraska Banker’s Association.
Pharmacological approaches to treat diabetic retinopathy – minority supplement (R01 DK064172-S1).
[04/03-03/06].
National Institutes of Health (NEI),
Bethesda, MD.

Pharmacological approaches to treat diabetic retinopathy (R01 DK064172). [04/03-03/06].

National Institutes of Health (NEI),
Bethesda, MD.
Subconjunctival route to prolong corticosteroid delivery (R03 EY013842). [08/01/03-07/31/06]. National Institutes of Health (NEI),
Bethesda, MD.
Ocular drug disposition from novel Alcon formulations.
[12/11/03-12/11/04]
.
Alcon Laboratories, Inc.,
Fort Worth, TX.
Ocular drug delivery research. 
[2002-present]. Unrestricted funding.
Santen Corporation,
Japan.
Retinal delivery of celecoxib to inhibit VEGF expression.  [2001]. UNMC seed grant.
Inhibition of VEGF expression and angiogenesis. [04/01 - 01/02]. Controlled Delivery Systems, Inc, Watertown, MA.
Deslorelin transport across bovine nasal tissue.  1[02/00 - 11/02]. Balance Pharmaceuticals, Inc., Santa Monica, CA.
Assessment of bovine nasal tissue for peptide drug transport: A feasibility study with deslorelin. [08/00 - 07/01]. Balance Pharmaceuticals, Inc., Santa Monica, CA.
Mechanisms and kinetics of degradation of deslorelin in nasal epithelial cells. [03/00 - 02/01]. Balance Pharmaceuticals, Inc., Santa Monica, CA.
Ocular absorption of levobetaxolol from novel formulations - 1. 
[10/98 -10/00].
Alcon Laboratories, Inc.,
Fort Worth, TX.
AAPS new investigator grant in pharmaceutics, drug delivery and pharmaceutical technology.
[08/98 - 07/00].
Unrestricted research funding.
Ocular absorption of levobetaxolol. [08/98 - indefinite]. Alcon Laboratories, Inc.,
Fort Worth, TX.
Systemic and ocular absorption of novel ARIs (R15 EY1177-03).
[03/97 - 02/00].
(Co-investigators: Jack DeRuiter and C. Randall Clark).
National Institutes of Health (NEI),
Bethesda, MD.
Production of budesonide particles for pulmonary delivery using supercritical fluid antisolvent precipitation technique.
[12/97 - 11/99]. (Co-investigator. Christopher B. Roberts, Department of Chemical Engineering).
Auburn University Biogrant Proposal, Auburn University, Auburn, AL.
Ocular absorption of drugs from Alcon formulations. [07/97 - 06/98]. Alcon Laboratories, Inc.,
Fort Worth, TX.
A preliminary bioequivalence study of phenylbutazone paste in horses. [04/97 - 08/97].
(Co-investigators: William R. Ravis, Ram Purohit, Sue H. Duran).
Med-Pharmex, Inc.,
Pomona, CA.
Mechanisms of transport of dideoxyinosine across cornea and conjunctiva. Future Life Science Scholars Program. [06/97 - 09/97]. (Role: Mentor for James Kelly, a high school student from Opelika). Sponsored by Howard Hughes Institute through a core grant to Auburn University.
A sustained release device for deslorelin in treating cystic ovarian disease in cattle. Future Life Science Scholars Program. [06/97 - 9/97]. (Role: Mentor for Sharon Williams, a student from Tuskegee University). Sponsored by Howard Hughes Institute through a core grant to Auburn University.
Fabrication and characterization of porous biodegradable membranes.  [08/96 - 10/96]. DPD Inc.,
2000 Turner St., Lansing, MI.
ELISA analysis of deslorelin in rabbit plasma samples. [10/95 - 12/95]. Balance Pharmaceuticals, Inc., 842 Las Casas Ave.,
Pacific Palisades, CA.
Ocular Absorption of drugs from ten formulations; [08/95 - 7/97]. Alcon Laboratories, Inc.,
6201 South Freeway,
Fort Worth, TX.
Influence of an anti-glaucoma agent on rabbit corneal and conjunctival ion transport; [03/95 - 2/96]. Sigma Xi Headquarters, 99 Alexander Drive- Box 13975, Research Triangle Park, NC.
Deslorelin: HPLC assay and nasal degradation (Role: Mentor for Megan Huff of Opelika). Future Life Science Scholars Program at Auburn University; [06/95 - 8/95]. Sponsored by Howard Hughes Institute.
Development and characterization of an in vitro model for drug and ion transport across rabbit nasal epithelial tissue. [05/95 - 04/96]. Auburn University Research Grant-in-Aid.
RIA and ELISA analysis of estradiol, testosterone, and deslorelin in human serum samples. [03/95 - ]. Balance Pharmaceuticals, Inc., 842 Las Casas Ave.,
Pacific Palisades, CA.
RIA and ELISA analysis of estradiol, testosterone, and deslorelin in rabbit plasma samples. [03/95 - ]. Balance Pharmaceuticals, Inc., 842 Las Casas Ave.,
Pacific Palisades, CA.
RIA and ELISA analysis of estradiol, testosterone, and deslorelin in rabbit plasma samples. [02/95 - ]. Balance Pharmaceuticals, Inc., 842 Las Casas Ave.,
Pacific Palisades, CA.

[Top]

Project (Role: Co-Investigator)

Funding Agency

Pharmacokinetics of nonsteroidal anti-inflammatory drugs in South American Camelids. [11/97-10/98].
(PI: Christine Navarre).

Morris Animal Foundation,
45 Inverness Drive East, Englewood, CO 80112
Assessment of self-learning ability: Validation of scales and outcome measures. [10/97].
(PI: Debbie C. Byrd).
Auburn University Research Grant-in-Aid proposal.
Novel GnRH agonist therapy for cystic ovaries in cattle.  [10/97 - 09/98].
(PI: James G.W. Wenzel).
USDA for Food Animal Health and Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL.

Corneal and conjunctival transport of novel aldose-reductase inhibitors. Future Life Science Scholars Program.
[6/97-9/97]. [Role: Co-advised (along with Jack DeRuiter) Erika Thomas, a high school student from Mississippi].

Sponsored by Howard Hughes Institute through a core grant to Auburn University.
A novel LHRH agonist therapy for cystic ovaries in cattle.  [10/96-9/97].
(PI: James Wenzel).
USDA for Food Animal Health and Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL.

Development of a nasally administered vaccine to combat Pasteurella haemolytica in cattle.  [10/96-9/97].
(PI: Sue Hudson Duran).

USDA for Food Animal Health and Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL.
Regional administration of ceftiofur for the treatment of septic foot conditions in cattle.  [10/95-9/96].
(PI: Christine B. Navarre).
USDA for Food Animal Health and Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL.
Development of a nasally administered vaccine to combat Pasteurella haemolytica in cattle. [10/95-9/96].
(PI: Sue Hudson Duran).
USDA for Food Animal Health and Disease Research, College of Veterinary Medicine, Auburn University, Auburn, AL.

[Top]